相关实验视频

Updated: Jul 28, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

管理一线转移性细胞癌:有利的风险疾病

Elizabeth Pan¹, Danielle Urman¹, Carmel Malvar¹

¹University of California San Diego, Moores Cancer Center, 3855 Health Sciences Drive, #0987, La Jolla, CA 92093-0987, USA.

Hematology/oncology clinics of North America

|May 31, 2023

概括

有有利风险的转移性细胞癌显示出更好的预后. 与sunitinib相比,免疫疗法和氨酸激酶抑制剂的组合改善了无进展生存率,但并没有改善整体生存率.

科学领域:

在瘤学瘤学.
临床试验临床试验
癌症生物标志物癌症生物标志物

背景情况:

转移性细胞癌 (mRCC) 风险分层对于治疗选择至关重要.
通过IMDC或MSKCC等工具识别的有利风险的mRCC,由于惰的生物学,通常有更好的预后.
了解有利风险的mRCC治疗疗效对于优化患者的治疗结果至关重要.

研究的目的:

评估免疫疗法和血管内皮生长因子氨酸激酶抑制剂组合相对于sunitinib在有利风险的转移性细胞癌的疗效.
在这个患者亚组中分析无进展生存 (PFS),客观反应率 (ORR) 和整体生存 (OS).

主要方法:

对第三阶段临床试验数据的分析.
组合疗法 (免疫疗法+VEGF-TKI) 和sunitinib之间的治疗结果的比较.
基于既定风险标准 (IMDC/MSKCC) 的患者分层.

主要成果:

与sunitinib相比,组合疗法证明了无进展生存率 (PFS) 和客观响应率 (ORR) 的改善.
在有利风险组的组合疗法中,没有观察到总体存活率 (OS) 的显著改善.
有有利风险的疾病特征与不同的治疗反应有关.

结论:

虽然组合疗法在有利风险的mRCC中提供PFS和ORR的好处,但与sunitinib相比,它们目前没有改善整体存活率.
风险分层仍然是预测治疗反应和指导转移性细胞癌治疗选择的关键因素.

关键词:

有有利风险的风险.免疫治疗是一种免疫疗法.细胞癌是细胞癌.在VEGF-TKI中.

更多相关视频

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...